FDA opens US to Lyrica generics
24-07-2019
CJEU backs Warner-Lambert in marketing authorisation dispute
18-02-2019
UK Supreme Court issues Warner-Lambert v Actavis ruling
14-11-2018
Pfizer expects $1.9bn loss due to patent expirations
31-07-2018
daneger / iStockphoto.com
The US Food and Drug Administration (FDA) has granted Pfizer paediatric exclusivity for Lyrica (pregabalin), extending the period of US market exclusivity for the drug by six months.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Pfizer, US Food and Drug Administration, Lyrica, pregabalin, patent extension, market exclusivity, paediatric exclusivity, patent expiry
